Biocardia, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Biocardia, Inc. on June 10, 2024. The report details equity sales conducted under an existing At The Market Offering Agreement (Sales Agreement) during the period from April 1, 2024, to June 10, 2024.
Key Financial Metrics
- Shares Sold: 335,112 shares of common stock.
- Gross Proceeds: Approximately $1.85 million.
- Remaining Capacity: $264,000 of shares available for issuance under the prospectus supplement dated December 6, 2024.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for these metrics; investors are directed to the Form 10-Q filed on May 14, 2024, for liquidity details.
Material Changes
The primary material event is the completion of share sales totaling $1.85 million in gross proceeds. This activity reduced the remaining capacity under the Sales Agreement to $264,000.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard legal disclaimers regarding the offer of securities. The report explicitly states it does not constitute an offer to sell shares in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the remaining $264,000 issuance capacity under the Sales Agreement.
- Review the Form 10-Q filed on May 14, 2024, for comprehensive liquidity and cash flow data.
- Confirm the average price per share derived from the $1.85 million proceeds and 335,112 shares sold.
- Check the effective Registration Statement on Form S-3 (File No. 333-275099) for full terms of the Sales Agreement.